Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma Therapies.

• Tác giả: Metodi Balev, Divaya Bhutani, Rajshekhar Chakraborty, Michael Sang Hughes, Suzanne Lentzsch, Markus Mapara, Jai Radhakrishnan
• Ngôn ngữ: eng
• Ký hiệu phân loại: 373.236 Lower level
• Thông tin xuất bản: England : European journal of haematology , 2025
• Bộ sưu tập: NCBI
• ID: 658439

Tóm tắt

Myeloma cast nephropathy (MCN) is a driver of renal failure in newly diagnosed multiple myeloma (NDMM) and has been historically associated with increased early mortality. Since patients with moderate to severe renal insufficiency are typically excluded from trials, we performed a retrospective study to characterize modern-era outcomes in MCN. We reviewed 274 consecutive NDMM patients from 2017 to 2023 at an academic center and identified 46 patients (16.8%) with MCN. Among them, 96% had received bortezomib and 67% anti-CD38